1. Concomitant inhaled corticosteroid resensitises cardiac β2-adrenoceptors in the presence of long-acting β2-agonist therapy

   • I. Aziz
   • L. C. McFarlane
   • B. J. Lipworth

   PHARMACODYNAMICS Pages: 377 - 381

2. The effect of nimesulide versus placebo on hemostasis in healthy volunteers

   • G. A. Marbet
   • M. L. Yasikoff Strub
   • D. A. Tsakiris

   PHARMACODYNAMICS Pages: 383 - 387

3. Aqueous humour concentration and the intraocular pressure-lowering effect of topical betaxolol before cataract surgery

   • E. Vainio-Jylhä
   • M.-L. Vuori
   • R. Huupponen

   PHARMACODYNAMICS Pages: 389 - 392

4. Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy

   • F. Menniti-Ippolito
   • M. Maggini
   • A. M. Walker

   PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Pages: 393 - 397

5. Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole

   • T. Andersson
   • E. Bredberg
   • I. Wilson

   PHARMACOKINETICS AND DISPOSITION Pages: 399 - 404

6. Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers

   • B. Hamon-Vilcot
   • S. Chaufour
   • F. Piette

   PHARMACOKINETICS AND DISPOSITION Pages: 405 - 409

7. Comparative pharmacokinetic study of oral and rectal formulations of artesunic acid in healthy volunteers

   • V. Navaratnam
   • S. M. Mansor
   • M. N. Abdullah

   PHARMACOKINETICS AND DISPOSITION Pages: 411 - 414

8. Pharmacokinetics of nimustine, methotrexate, and cytosine arabinoside during cerebrospinal fluid perfusion chemotherapy in patients with disseminated brain tumors

   • N. Morikawa
   • T. Mori
   • S. Hori

   Pharmacokinetics and disposition Pages: 415 - 420

9. Zolpidem 10 mg given at daytime is not antagonized by 300 mg caffeine in man

   • M. J. Mattila
   • M.-L. Nurminen
   • J. Vanakoski

   PHARMACOKINETICS AND DISPOSITION Pages: 421 - 425

10. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity Role of CYP2D6 and CYP2C19 in longevity

    • L. Bathum
    • K. Andersen-Ranberg
    • B. Jeune

    PHARMACOKINETICS AND DISPOSITION Pages: 427 - 430

11. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations

    • S. Wanwimolruk
    • S. Bhawan
    • S. C. W. Chalcroft

    PHARMACOKINETICS AND DISPOSITION Pages: 431 - 435

12. Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6

    • H. Hadidi
    • Y. Irshaid
    • J. R. Idle

    PHARMACOKINETICS AND DISPOSITION Pages: 437 - 441

13. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy

    • K. M. Jorga
    • B. Fotteler
    • G. Zürcher

    PHARMACOKINETICS AND DISPOSITION Pages: 443 - 447